A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00461006
First received: April 16, 2007
Last updated: September 22, 2014
Last verified: September 2014
  Purpose

This 2 arm study will compare the effects of aleglitazar and Actos, added to pre existing oral antihyperglycemic therapy and/or diet and exercise, on renal funct ion in patients with type 2 diabetes, and normal or mildly impaired renal functi on. Eligible patients will be randomized to receive either aleglitazar 0.6mg p.o or Actos 45mg p.o. daily. Renal function and efficacy parameters will be asses sed at intervals during the treatment period. The anticipated time on study trea tment is 3-12 months, and the target sample size is 100-500 individuals.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: Actos
Drug: aleglitazar
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Relative change from baseline in glomerular filtration rate [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Relative change from baseline in ERPF and UACR [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
  • Absolute change in HbAlc, FPG and FPI. [ Time Frame: End of treatment ] [ Designated as safety issue: No ]
  • AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 176
Study Start Date: June 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: aleglitazar
0.6mg po daily
Active Comparator: 2 Drug: Actos
45mg po daily

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • type 2 diabetes for >=1 month;
  • drug naive, or receiving stable oral antihyperglycemic medication;
  • HbAlc 6.5-10.0% at screening.

Exclusion Criteria:

  • type 1 diabetes;
  • current or previous treatment with insulin;
  • history of renal disease other than diabetic nephropathy;
  • uncontrolled hypertension;
  • clinically significant cardiovascular disease;
  • CHF NYHA 3-4.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00461006

  Hide Study Locations
Locations
United States, Arizona
Peoria, Arizona, United States, 85381
United States, Arkansas
Jonesboro, Arkansas, United States, 72401
United States, California
Fresno, California, United States, 93720
Los Gatos, California, United States, 95032
Mission Viejo, California, United States, 92691
United States, Florida
Jacksonville, Florida, United States, 32216-4313
United States, Nebraska
Omaha, Nebraska, United States, 68131
United States, North Carolina
Charlotte, North Carolina, United States, 28211
United States, Ohio
Marion, Ohio, United States, 43302
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16602
United States, Texas
Arlington, Texas, United States, 76014
Arlington, Texas, United States, 76017
Dallas, Texas, United States, 75231
Midland, Texas, United States, 79707
San Antonio, Texas, United States, 78284
United States, Virginia
Norfolk, Virginia, United States, 23510
Mexico
Chihuahua, Mexico, 31328
Chihuahua, Mexico, 31238
Hermosillo, Mexico, 83067
Metepec, Mexico, EMEX52140
Mexico City, Mexico, 11650
Mexico City, Mexico, 14050
Mexico City, Mexico, 14000
Monterrey, Mexico, 64000
Zapopan, Mexico, 45200
Puerto Rico
Manati, Puerto Rico, 00674
Ponce, Puerto Rico, 00717-322
Toa Baja, Puerto Rico, 00949
Russian Federation
Moscow, Russian Federation, 109472
Moscow, Russian Federation, 127486
Moscow, Russian Federation, 127299
Moscow, Russian Federation, 125101
Moscow, Russian Federation, 129110
Saratov, Russian Federation, 410038
St Petersburg, Russian Federation, 197198
St Petersburg, Russian Federation, 191025
St Petersburg, Russian Federation, 198205
St. Petersburg, Russian Federation, 199106
Tumen, Russian Federation, 625023
Yaroslavl, Russian Federation, 150062
Ukraine
Dnipropetrovs'k, Ukraine, 49005
Dnipropetrovs'k, Ukraine, 49060
Donetsk, Ukraine, 83114
Donetsk, Ukraine, 83003
Kharkiv, Ukraine, 61039
Kharkov, Ukraine, 61178
Kiev, Ukraine, 2125
Kiev, Ukraine, 2091
Kiev, Ukraine, 02091
Lugnansk, Ukraine, 91045
Poltava, Ukraine, 36024
Ternopil, Ukraine, 46002
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00461006     History of Changes
Other Study ID Numbers: BC20653
Study First Received: April 16, 2007
Last Updated: September 22, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on September 30, 2014